Eri L M, Urdal P, Bechensteen A G
Department of Surgery (Division of Urology), Ullevaal University Hospital, Oslo, Norway.
J Urol. 1995 Jul;154(1):100-4.
The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia. In the 26 patients receiving leuprolide the mean total cholesterol level increased by 10.6%, high density lipoprotein cholesterol by 8.2% and triglycerides by 26.9% (p = 0.003, 0.052 and 0.050, respectively). Low density lipoprotein cholesterol levels were unchanged. Apolipoprotein A1 increased by 13.2% (p = 0.001), while apolipoprotein B, fibrinogen, thrombocytes and plasminogen activator inhibitor were unchanged. Hemoglobin decreased by 1.2 gm./100 ml. without a concomitant decrease in serum erythropoietin concentration. These changes act in different directions with regard to cardiovascular risk and the overall effect is difficult to assess.
在一项纳入50例可评估的良性前列腺增生患者的对照双盲研究中，调查了长期注射促黄体生成激素释放激素激动剂亮丙瑞林微球对心血管危险因素的影响。在接受亮丙瑞林治疗的26例患者中，总胆固醇水平平均升高了10.6%，高密度脂蛋白胆固醇升高了8.2%，甘油三酯升高了26.9%（p值分别为0.003、0.052和0.050）。低密度脂蛋白胆固醇水平未发生变化。载脂蛋白A1升高了13.2%（p = 0.001），而载脂蛋白B、纤维蛋白原、血小板和纤溶酶原激活物抑制剂未发生变化。血红蛋白下降了1.2克/100毫升，而血清促红细胞生成素浓度并未随之下降。这些变化在心血管风险方面作用方向不同，总体影响难以评估。
